Results 31 to 40 of about 24,887 (213)
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial [PDF]
, 2019 BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is the most frequent genetically determined renal disease. In affected patients, renal function may progressively decline up to end-stage renal disease (ESRD), and approximately 10% of those ...
Flavio Gaspari +66 more
core +1 more source
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. [PDF]
PLoS ONE, 2012 BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Andrea Giustina +5 more
doaj +1 more source
Graves' dermopathy: does octreotide scintigraphy predict the response to octreotide treatment? [PDF]
, 1996 We report on three patients with severe Graves' dermopathy who were treated with octreotide despite a negative octreotide scintigraphy. One patient showed a complete recovery while two others had a partial response.
van der Pijl, J. W. +3 more
core +1 more source
Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy [PDF]
, 1998 We compared the internalization of [90Y-DOTA0,Tyr3]octreotide and [111In-DOTA0,Tyr3]octreotide with that of [125I-Tyr3]octreotide and [111In-DTPA0]octreotide in the subtype 2 somatostatin receptor (sst2)- positive rat pancreatic tumour cell lines CA20948
Mäcke, H.R. (Helmut) +7 more
core +1 more source
Pediatric Investigation, 2020 Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present
Bingyan Cao +8 more
doaj +1 more source
Octreotide Use in Neonates:A Case Series [PDF]
, 2018 Background and Objective: Octreotide is a somatostatin analogue and has been used off-label for a variety of conditions. There are no specific guidelines for the use of octreotide in neonates and its safety and efficacy have not been systematically ...
Syed Ahmed Zaki +5 more
core +1 more source
Case Reports in Gastrointestinal Medicine, 2019 We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of ...
Matthew H. Kemm +4 more
doaj +1 more source
Cellular Physiology and Biochemistry, 2018 Background/Aims: Hepatocellular carcinoma (HCC) is a major threat to human health. The condition carries a high risk of death; 45% of new cases occur in China.
Chuan-Zhong Huang +5 more
doaj +1 more source
Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome [PDF]
, 1999 PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has
Ronald Bukowski +8 more
core +1 more source
Frontiers in OncologyMeningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based ...
Carlen A. Yuen +15 more
doaj +1 more source